Synonyms: claudiximab | GC-182 | IMAB-362 | IMAB362
Compound class:
Antibody
Comment: Zolbetuximab (IMAB362) is an investigational, first-in-class monoclonal antibody targeting the cell surface molecule claudin18.2 (CLDN18.2), a pan-cancer drug target [4,8]. Claudin-18 is a tight-junction protein. Splice variant 2 is reported to be a highly selective cell lineage marker of gastric mucosal cells, and it is an active molecular target for tumour-targeted immunotherapy [1-3]. CLDN18.2 is retained on malignant transformation and is expressed in a significant proportion of primary gastric cancers and their metastases, and ectopic expression of CLDN18.2 is identified in distinct histologic subtypes of pancreatic (primary tumour and metastases) [9], esophageal, ovarian, and lung tumours [4]. Zolbetuximab binds to the first extracellular N-terminal domain which is unique to the CLDN18.2 splice variant [4,9].
|
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
10473 | zolbetuximab |
Synonyms |
claudiximab | GC-182 | IMAB-362 | IMAB362 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 753 |
Other databases | |
GtoPdb PubChem SID | 315661285 |
Search PubMed clinical trials | zolbetuximab |
Search PubMed titles | zolbetuximab |
Search PubMed titles/abstracts | zolbetuximab |